Nishaki Mehta is a Cardiology physician. OpenAlex indexes 180 publications with 838 citations (h-index 16); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 W 13 Mile Rd
Royal Oak, MI 480736712
Telephone
248-898-4163Provider last certified this registry record 29 Jul 2022.
Clinical trials
- Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)
Sponsor: Corewell Health East
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202535 payments$33,460openpaymentsdata.cms.gov ↗
- Medtronic, Inc.Program year202519 payments$11,698openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202529 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
65.7%Beta blocker18.7%Metoprolol Succinate56%Carvedilol23%Metoprolol Tartrate21%Part D<11 patientsAntiarrhythmic16.1%Amiodarone Hcl54%Flecainide Acetate28%Multaq18%Part D<11 patients+ 7 more classes in this area
Blood & clotting
31.2%Factor Xa inhibitor31.2%Eliquis80%Xarelto20%Part D≥52 patientsMetabolism & gastrointestinal
3.2%SGLT2 inhibitor3.2%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long‐Term Impact of GLP‐1 Receptor Agonists on AF Recurrence After Ablation in Obese Patients
Journal of Cardiovascular Electrophysiology
2025 - Risk of Stillbirth and Preterm Birth in Cardiac Arrhythmias During Pregnancy
JACC. Clinical electrophysiology
2025 - State of the art of mobile health technologies use in clinical arrhythmia care
Communications Medicine
2024 - A single-center trial of electrographic flow mapping and concomitant voltage mapping in sinus rhythm and atrial fibrillation (FLOW EVAL-AF)
Journal of Interventional Cardiac Electrophysiology
2024 - Atrial fibrillation considerations in the fourth trimester (postpartum period)
Journal of Interventional Cardiac Electrophysiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”